Form 4: Tenax Therapeutics CEO Buys Shares
Insider Transaction (Form 4)
Christopher Thomas Giordano, CEO and a Director of Tenax Therapeutics, Inc., purchased 10,850 shares of common stock on September 11, 2026.
Summary
- Open-market purchase: acquired 6,000 Common Stock at $1.88 ($11,250) on September 11, 2026; holds 17,324 after (Direct).
- Open-market purchase: acquired 4,850 Common Stock at $1.82 ($8,837) on September 15, 2026; holds 22,174 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $20,087, committing personal capital to the stock.
Insider Transactions
Christopher Thomas Giordano — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Open-market purchase | Common Stock | 6,000 | $2 | $11.3K | 17,324 |
| 2026-09-15 | Open-market purchase | Common Stock | 4,850 | $2 | $8.8K | 22,174 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Open-market purchase (6,000 shares) |
| 2026-09-15 | Open-market purchase (4,850 shares) |
Keywords
insider transaction, Form 4, TENX, TENAX THERAPEUTICS, INC., bullish, Christopher Thomas Giordano
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.